Ignite Creation Date:
2025-12-18 @ 8:53 AM
Ignite Modification Date:
2025-12-23 @ 11:16 PM
Study NCT ID:
NCT01446276
Status:
None
Last Update Posted:
2014-04-28 00:00:00
First Post:
2011-10-03 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease
Sponsor:
None
Organization:
Study Overview
Official Title:
Long-term Investigation of Resveratrol on Lipid Turnover in Obese Men With Nonalcoholic Fatty Liver Disease. Effects on Liver Fat Content and Basal and Insulin Stimulated FFA and VLDL-triglyceride Metabolism
Status:
None
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate potential metabolic effects of resveratrol in obese healthy men with non-alcoholic fatty liver disease.
The investigators hypothesize that resveratrol will:
* decrease hepatic very-low-density-lipoprotein-triglyceride (VLDL-TG) secretion
* decrease liver fat content
* increase insulin sensitivity
The investigators will look at changes in:
* lipid turnover (VLDL-TG kinetics, palmitate kinetics, indirect calorimetry)
* liver fat content (MR liver spectroscopy)
* insulin sensitivity (glucose kinetics during hyperinsulinaemic euglycaemic clamp)
* body composition (DXA and MRI)
* lipase activity and fat cell size (fat biopsy from abdominal and femoral adipose tissue)
The investigators hypothesize that resveratrol will:
* decrease hepatic very-low-density-lipoprotein-triglyceride (VLDL-TG) secretion
* decrease liver fat content
* increase insulin sensitivity
The investigators will look at changes in:
* lipid turnover (VLDL-TG kinetics, palmitate kinetics, indirect calorimetry)
* liver fat content (MR liver spectroscopy)
* insulin sensitivity (glucose kinetics during hyperinsulinaemic euglycaemic clamp)
* body composition (DXA and MRI)
* lipase activity and fat cell size (fat biopsy from abdominal and femoral adipose tissue)
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: